Evidence for the involvement of genetic factors in the pathogenesis of bipolar affective disorder is now well established.
Evidence for the involvement of genetic factors in the pathogenesis of bipolar affective disorder is now well established. 1 However, the mode of inheritance is nonmendelian and this makes the identification of susceptibility loci difficult. A short-cut to localisation of a disease gene for an oligogenic/multifactorial disorder such as bipolar disorder may come from observation of cosegregation with a monogenic trait. We have described a family (pedigree 324) in which there was cosegregation of major affective disorder and Darier's disease, a dominantly inherited skin disorder, and hypothesised that this reflects genetic linkage between genes involved in these disorders. 2 Genetic mapping studies have placed the locus for Darier's disease on chromosome 12q23-q24. [3] [4] [5] [6] [7] We conducted subsequent linkage studies (1995) upon 45 bipolar families (without Darier's disease). These results showed some evidence in favour of linkage with chromosome 12q markers with maximum evidence at a trinucleotide repeat marker within intron 1 of the phospholipase A2A (PLA2A) gene. 8 Evidence for linkage was more significant when analysing the 22 families comprising the Cardiff centre sample, which were expected to be most genetically similar to pedigree 324.
Phospholipase A2 is a superfamily of distinct enzymes 9 that play a central role in a number of cellular processes including host defence, signal transduction and phospholipid digestion/metabolism. 10 They are a diverse class of enzymes with regard to localisation, regulation, sequence, structure and role of divalent metal ions. 10 All PLA2s perform the same enzymatic reaction involving the hydrolysis of the sn-2 fatty acid acyl bond of phospholipids to yield free fatty acids and lysophospholipids and have an important role in regulation of lipid membrane fluidity. 11 Hibbeln et al 11 proposed that excess PLA2 activity disrupts membrane fluidity and composition and therefore affects the activity of membranedependent proteins, such as neurotransmitter receptoreffector complexes.
In the present study mutational analysis was performed on the human PLA2A gene on chromosome 12q. Linked polymorphisms were found within exon three and the upstream region. However, the allele and genotype frequencies of these polymorphisms in samples of individuals affected with bipolar disorder (n = 96) did not differ from those of control subjects (n = 96), suggesting that these variations are not associated with bipolar affective disorder.
The PLA2A gene on chromosome 12 encodes a secretory form of PLA2 found predominantly in the pancreas. 12 This might seem to make it an implausible candidate for bipolar disorder. However, it has been shown that secretory PLA2 has significant effects upon neuronal cells 13 demonstrable in vitro and thought to have significance in vivo.
14 Glutamate receptors within the brain may be involved in the mode of action of some antidepressant drugs and therefore, may be involved in the pathogenesis of depression. 15 The presence of PLA2 has been shown to accompany a modulation in metabotropic binding of AMPA receptors, a subtype of glutamate receptor. Free fatty acids produced by the enzymatic activity of PLA2 have been shown to exert a modulatory effect upon these receptors. 16 As well as the possible roles of PLA2 metabolites in glutamate receptor modulation the modification of the glutamate receptor complex lipid environment caused by PLA2 may also have regulatory effects upon receptor function. 17 It is also of note that twelve glutamate receptors have been cloned to date, four of which map to chromosomal regions of interest in BPD/MD. These include GLUR3 which maps to chromosome Xq25-q26, 18, 19 GLUR4 mapping to chromosome 11q22-q23, 18, 20, 21 GLUR5 which maps to chromosome 21q21-q22.1 22, 23 and an NMDA receptor subunit gene mapping to 16p13. 24, 25 Dawson and colleagues 13 undertook allelic association studies analysing several markers on chromosome 12q encompassing the Darier's disease critical region in a sample of 54 unrelated bipolar probands and 56 unrelated controls. Evidence for association was found with a marker in intron 1 of PLA2A (P Ͻ 0.01, uncorrected for multiple testing), although after correction for multiple testing this finding failed to reach conventional levels of statistical significance (P Ͻ 0.07). We subsequently tested for allelic association at this marker employing a larger independent sample of Caucasian bipolar probands (n = 127) and controls (n = 223). 26 This study was unable to replicate the findings of Dawson et al 13 (P = 0.090), and indeed, did not even display a trend towards the findings of this study.
The PLA2A intron 1 based marker is an AAT repeat polymorphism and to the best of our knowledge is not known or suspected to have any functional signifi-cance. 26 Little can be inferred from a negative association 27 finding with such a non-functional polymorphism and it remains possible that a different polymorphism within the coding or control regions of the PLA2A gene may be involved in the pathogenesis of bipolar disorder.
The human PLA2A gene comprises four exons of 33 bp, 159 bp, 127 bp, and 124 bp respectively. 12 The gene spans 4.9 kb of genomic DNA. Exon 1 encodes a 36-bp 5Ј untranslated region and a signal sequence. Exon 2 encodes a key active site residue (His-48) and a calcium-binding loop. Exon 3 encodes a second key active site residue and a ␤-wing region. Exon 4 encodes a highly conserved region (around Ala102 and -103) also involved in the active site. The published PLA2A genomic sequence also includes approximately 500 bp of upstream region containing putative TATA, CCAAT and GC sequences (at positions −26, −91 and −49 relative to transcription initiation at position 1).
SSCP analysis of PCR fragments containing exon 3 gave rise to four different band profiles suggesting the presence of polymorphism. SSCP analysis of PCR products of upstream region segment A gave rise to three different band patterns. Analysis of exons 1, 2, and 4, and upstream region segments B, C, and D gave no indication of potential sequence variation in these regions. Sequencing analysis of PCR products containing exon 3 revealed the presence of two polymorphisms. Analysis of upstream region segment A showed the presence of two polymorphisms.
Direct sequencing of exon 3 PCR products that displayed the four variant SSCP profiles using primers 3F and 3R revealed the presence of two distinct DNA sequence variations (see Figure 1a and b). The first was a T to C transition in exon 3 at position 2714 (base pair 3250 of the Genbank PLA2A genomic sequence). The second variation was a G to A transition at basepair 2786 (base pair 3322 of the Genbank sequence). Sample 4 was homozygous G at this position but possessed a third conformer which concurred with the heterozygous status at position 2714 for this sample (ie TC). Consensus DNA sequences were prepared and translated using the DNAstar program which revealed both changes to occur at third codon base positions and in both cases the variations wre synonymous. These polymorphisms have also been described by Beuten et al. 28 Sequencing data produced from PCR products using primers AF and AR yielded a number of non-specific terminations. Therefore, PCR products from samples displaying the three variant SSCP profiles were cloned into the pMOSblue T-vector and the inserts sequenced using universal vector primers. Data revealed the presence of a C to A transversion polymorphism at position −486 (basepair 50 of the Genbank sequence) (see Figure 1c ). This polymorphism occurred in the PLA2A upstream region and therefore in an area where potential regulatory sequences may occur. Use of the GRAIL program 29 (through NIX, HGMP Cambridge) failed to detect POL II promoter sequences within this region.
All three polymorphisms were analysed in the entire case-control sample employing PCR and RFLP analysis (see Table 1 for details). Table 2 shows the distribution of alleles and genotypes in the control and proband samples for each polymorphism. For each polymorphism, control and proband samples were close to Hardy-Weinberg equilibrium and allele and genotype distributions for each polymorphism were similar in the proband and control sample groups with no comparison approaching conventional levels of statistical significance (P Ͼ 0.33 for each comparison, even before allowing for multiple testing).
We found evidence of linkage disequilibrium between the three loci: (−486C→A-2714T→C, P = 0.00052, disequilibrium constant, D = 0.031; −486C→A-2786G→A, P Ͻ 0.000001, D = 0.092; 2714T→C-2786G→A, P = 0.034, D = 0.012). However, inspection of haplotypes did not suggest that any haplotype showed statistically significant preferential association with disease status, even before allowing for multiple testing.
In summary, the data produced enabled the identification of three polymorphisms. Two were located within exon three, were shown not to cause changes in amino acid sequence, and were also characterised by Beuten et al. 28 The third polymorphism was identified within the upstream region of the gene.
To the best of our knowledge there are no studies currently published that implicate this area of the Position of polymorphisms is relative to start of translation. upstream region in transcriptional regulation of PLA2A and Seilhamer and colleagues 12 have identified a number of putative promoter motifs that occur downstream of this area. By use of the GRAIL program 29 it was possible to exclude the presence of POL II promoter sequences. Subsequent analysis of this polymorphism in the entire proband and control sample failed to support its involvement in predisposition to disease.
The two silent mutations identified in exon 3 of PLA2A failed to show association with bipolar disorder in our sample, although, as previously highlighted, little can be inferred from negative association data obtained from analysis of non-functional polymorphisms despite them being tightly linked to the putative disease gene in question. This fact is exemplified by the observation that alleles at polymorphisms identified in the MAO-A and -B genes fail to show evidence of linkage disequilibrium despite the propinquity of these genes. 27 Haplotype analysis of all three polymorphisms showed no evidence of association between any particular haplotype and disease status.
In assessing any negative finding in a study such as ours it is essential to consider both: (1) technical issues regarding the sensitivity of the assay to detect DNA sequence variants; and (2) the statistical power of the sample used.
The ability of SSCP to detect mutations within DNA fragments is dependent upon a number of factors. 30 The length of the fragment and the position of a mutation within it has significant effects upon detection rates. The average detection rate for a 212-bp fragment or less has been shown to be 79%. It has been noted that DNA sequence flanking mutations can have profound effects upon mutation detection and in some cases can lower rate of mutation detection. Also, the conditions employed during electrophoresis of single stranded conformers can introduce further variations in detection rate. It may therefore be prudent to employ other more sensitive methods of mutational detection in order to further verify that all mutations have been detected. One such method utilises liquid chromatography for analysis of DNA fragments (DHPLC) 31 such that DNA heteroduplexes behave differently to homoduplexes when applied to a liquid chromatography column. This method is proving extremely sensitive for detection of mutations.
We have used a two-stage design in our study. The screening stage used a sample of 42 bipolar probands and 42 controls in order to identify polymorphisms within PLA2A of potential relevance to disease susceptibility. Simple application of the binomial expansion shows that, using a detection method with 100% sensitivity, this sample has power exceeding 98% to detect a polymorphism in which the rarer allele has frequency of 5% or greater. Taking account of the reduced sensitivity of the detection method (as mentioned above) we can, thus, expect to identify approximately 80% of polymorphic sites of at least moderate frequency of the rarer allele. In the screening stage we identified three bi-allelic polymorphisms which had frequencies of the rarer allele of approximately 0.11, 0.17 and 0.43. No significance test approached conventional levels of statistical significance with P Ͼ 0.6 for all tests. Power calculations show that using the extremely relaxed test size (significance criterion) of 0.4 and a two-tailed test, our second-stage sample (96 probands, 96 controls) has power Ͼ99% to detect any susceptibility allele conferring an increased risk, as measured by the odds ratio (OR), of OR = 3, power Ͼ93% to detect any susceptibility allele conferring an increased risk of OR = 2 and power Ͼ70% to detect any susceptibility allele conferring an increased risk of OR = 1.5.
In conclusion, we have undertaken mutational analysis of both coding and upstream regions of the PLA2A gene and have found no evidence of genetic variation that plays a major role in influencing susceptibility to bipolar disorder. Our two-stage approach provides power of approximately 80% to identify potentially relevant polymorphisms and for the three polymorphisms identified we can rule out even modest effect sizes (OR 1.5-2.0) with a high degree of confidence.
Materials and methods

Subjects
Written informed consent was obtained from both patients and control subjects after details of the relevant procedures had been explained fully. The study was approved by the relevant research ethics committees. All patient and control subjects were Caucasians born in the United Kingdom. In each case both parents were born in the United Kingdom or Ireland.
Bipolar probands
Ninety-six unrelated British Caucasians (36 male, mean age 44 years, standard deviation 14 years) meeting DSM-IV 32 criteria for bipolar I disorder were recruited from psychiatric outpatient clinics in South Wales and the Midlands of England. Probands were interviewed by a trained psychiatrist using either SADS-L (Schedule for Affective Disorders and Schizophrenia-Lifetime version) 33 modified to provide diagnostic information for DSM-IV or by SCAN (Schedules for Clinical Assessment in Neuropsychiatry), 34 and hospital records obtained. Best estimate lifetime diagnoses were made upon the basis of all available clinical data. It should be noted that we have previously demonstrated highly satisfactory agreement at the level of final diagnostic classification between data elicited by SADS-L and by the Present State Examinations 9 (PSE-9) 35 or 10 (SCAN). 36, 37 Seventy probands had a first or second degree relative who had received psychiatric treatment and 20 of these probands were from families in which there were at least two other cases of bipolar disorder. Thirteen of these probands came from families which showed increased allele sharing with markers in the 12q23-q24.1 region in our linkage study. 8 
Controls
Unrelated British Caucasian controls were recruited from a local branch of the National Blood Transfusion Service (Wales). They were not screened for the absence of psychiatric illness, although it should be noted that it is the policy of the National Blood Transfusion Service not to take donations from individuals on medication. Group matching was performed to obtain a control group of 96 subjects with similar age and sex distribution to the bipolar proband group.
PCR amplification of PLA2A exons 1-4, and the published upstream region
The PLA2A genomic DNA sequence was obtained from Genbank (accession numbers M21056 and M14965). Oligonucleotide primers for PCR analysis were designed for each exon to flanking non-exonic sequences. PCR primers were designed for the published upstream region in four discrete sections such that each PCR fragment overlapped the adjacent by a minimum of 50 bp and each PCR fragment was ensured not to exceed 275 bp. 30 High molecular weight genomic DNA was employed for PCR analysis isolated from lymphocytes by phenol/chloroform extraction. The analysis of each exon and upstream region fragment was carried out initially upon a subset of the patient and control sample described above. This sub-set consisted of 42 bipolar probands and 42 matched controls. One affected member from each of 20 multiply affected bipolar families was also analysed in addition to the 42 proband sub-set described above.
Primer sequences are displayed 5′-3′, forward (F) and reverse (R). The predicted sizes of the amplified PCR fragments are shown in base pairs in parentheses after each reverse primer sequence. 
SSCP analysis of PCR-amplified products
SSCP analysis was carried out by electrophoresis of 5 l of PCR reaction through 10% non-denaturing polyacrylamide (49:1 acrylamide:bis, Sigma-Aldrich Co, Poole, UK) at 70 V for 16 h at both room temperature and at 4°C. This analysis was carried out at both temperatures in the first instance and thereafter at the optimal temperature for each PCR fragment or at both temperatures if no band-shifts were apparent from initial screening. DNA was visualised by silver staining.
DNA sequencing studies
Sequencing reactions were carried out on selected samples which were chosen on the basis of their SSCP profiles. Sequencing analyses were performed on both strands of double-stranded PCR products using the appropriate forward and reverse PCR primers. Radioactive DNA cycle sequencing was performed using the Thermosequenase kit (Amersham) according to the manufacturer's instructions. However, when sequencing reactions were performed upon upstream region PCR fragment A directly, numerous inconsistent terminations were observed. In this case PCR products were cloned into the pMOSBlue T-vector (Amersham) and analysed using universal vector-based primers and radioactive cycle sequencing as above.
DNA sequence analysis DNA sequence analysis as performed using the Lasergene DNAstar program. DNA sequence analysis was performed using the Nucleotide Identify X program as implemented at the Human Genome Mapping Project (HGMP), Cambridge.
Restriction fragment length polymorphism (RFLP)
analysis DNA sequence variations identified in exon three and upstream region fragment A were analysed in the entire proband and control sample by utilising restriction endonucleases whose sites were either created or inactivated by the sequence variations observed. In the case of the exon 3 position 28 polymorphism, a PCR-RFLP assay was developed using the approach employed by Arinami et al. 38 A variant antisense primer was developed for this assay employing primer 3F as the sense primer. This primer denoted 3Rvar. is as follows: GTCCAGCTTCTTGGCCCGG. This primer enabled a BsiE1 site to become activated depending upon the polymorphism itself. We verified that SSCP profiles scored for the SSCP screening sample subset concurred with the RFLP patterns observed. Details of the polymorphisms and enzymes employed for their analysis can be seen in Table 1 .
Statistical analysis
Departure from Hardy-Weinberg equilibrium was tested using a 2 goodness-of-fit test. Statistical significance of difference between allele distributions was assessed using 2 tests. For genotype distributions some cells in contingency tables had values below 5. In order to assess the statistical significance of genotype distributions we therefore used a Monte-Carlo method as implemented in CLUMP. 39 This determines a P value by estimating by simulation the proportion of times the observed 2 for the contingency table might be expected to occur by chance, conditional on the marginal totals of the table.
Linkage disequilibrium between loci was analysed using ASSOCIATE, 40 a chi-square test to distinguish allelic association from other causes of phenotypic association between two loci.
